Comfort Systems USA Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Comfort Systems USA Inc trades at $1,520 (market cap $57.25B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Comfort Systems USA Inc is far larger — about 11.7× Travere Therapeutics Inc. Common Stock's market cap, and Comfort Systems USA Inc pays a 0.22% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 42 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FIX | TVTX | |
|---|---|---|
Market Cap | $57.25B | $4.88B |
Volume | 459,246 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $2.07K | $67.52 |
52-Week Low | $790.72 | $26.79 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | $55.72B | $5.01B |
Dividend Yield | 0.22% | — |
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,626.64, down 0.7% with bearish technical signals but strong fundamentals. The company demonstrates robust earnings momentum with three consecutive quarterly beats and impressive profitability metrics including 55.29% ROE. Recent acquisition of Hunt Electric expands Western electrical scale with $250M in annualized revenue. Technical indicators show bearish momentum with support at $1,611 and resistance at $1,687.
Outlook remains positive with analyst consensus price target of $2,080 representing 28% upside potential. Key opportunities include data center infrastructure demand and modular expansion, while risks involve project execution challenges and market volatility. The stock offers growth exposure to essential AI infrastructure services with strong institutional backing.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →